Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Aug 2004
Randomized Controlled Trial Clinical TrialN-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
We performed a study to assess the efficacy of fenoldopam mesylate (a specific agonist of the dopamine-1 receptor) as compared with N-acetylcysteine (NAC) in preventing contrast agent-associated nephrotoxicity (CAN). ⋯ N-acetylcysteine seems to be more effective than fenoldopam in preventing CAN.
-
J. Am. Coll. Cardiol. · Aug 2004
Randomized Controlled Trial Clinical TrialCo-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans.
The goal of this study was to test the hypothesis that NCX-4016 may have broader anti-inflammatory and antithrombotic effects as well as better gastric tolerability than aspirin in humans. ⋯ NCX-4016 is equally effective as aspirin in inhibiting cyclooxygenase activity. However, NCX-4016 causes less gastric damage and prevents monocyte activation. Larger multicenter trials are warranted to establish clinical efficacy and safety of NCX-4016.